The Swiss laboratory NOVARTIS is looking to buy some or all of the activities of HEXAL, the German number two in the production of generic medicines. NOVARTIS is said to be prepared to pay between 2.5 and 3 billion EUR. HEXAL's turnover was 1.35 billion EUR in 2004 and employs 7400. It sells over 250 products.